A Double-Blind, Double Dummy, Randomized, Phase 1B, Nitrofurantoin Con
Research payments
$3,314,949
Through program year 2025, $3,314,949 in research payments was reported against A Double-Blind, Double Dummy, Randomized, Phase 1B, Nitrofurantoin Con, across 271 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $636,767 | 90 |
| 2024 | Research | $1,658,968 | 104 |
| 2023 | Research | $941,542 | 62 |
| 2022 | Research | $77,672 | 15 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Mark Rosenthal Miami, FL Named on 26 payments
- Marcy Goisse Uniontown, PA Named on 23 payments
- Deirdre McMullen Missouri City, TX Named on 22 payments
- Luis Martinez Doral, FL Named on 16 payments
- Faisal Amin Brooklyn, NY Named on 14 payments
- James Lilly Dallas, TX Named on 13 payments
- Caroline Mbogua Magnolia, TX Named on 11 payments
- Marina Raikhel Torrance, CA Named on 10 payments
- Jose Carpio Miami Lakes, FL Named on 10 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.